Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer
02 September 2020 - 10:01PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
products for serious rare and ultra-rare genetic diseases, today
announced that it has appointed Mardi C. Dier as Executive Vice
President and Chief Financial Officer (CFO), effective November 2,
2020. Ms. Dier will be responsible for leading the corporate
finance, strategy, investor relations, corporate communications,
and information technology functions. She will report to Emil D.
Kakkis, M.D., Ph.D., Ultragenyx’s Chief Executive Officer, and will
serve on the executive leadership team. Ultragenyx had previously
announced the planned transition of CFO Shalini Sharp. Ms. Sharp
will remain as CFO until Ms. Dier starts in November and will
consult for the company for six months after.
“We welcome Mardi to Ultragenyx and its leadership team at an
important time as we build upon our solid foundation and recent
successes in treating patients with serious rare diseases and
strive to grow the company to the next level. Mardi is a proven
industry leader with financial and strategic expertise which will
serve to fortify Ultragenyx’s efforts in advancing our global
commercial opportunities and our promising pipeline addressing
important diseases with innovative therapies,” said Dr. Kakkis. “We
also want to thank Shalini for her incredible contribution and
dedication to the success thus far of Ultragenyx. We will miss her
and sincerely wish her well with her next endeavors.”
Ms. Dier joins Ultragenyx from Portola Pharmaceuticals, where
she served as Chief Financial Officer from 2006 to 2018 when her
role was expanded to include Chief Business Officer from 2018
through its acquisition by Alexion Pharmaceuticals in 2020. During
her tenure at Portola, she successfully led a series of private,
public, and alternative financings and led the company through its
pivotal transition into a commercial organization. Prior to
Portola, she served as Vice President of Investor Relations at
Chiron Corporation from 2003 to 2006. Earlier in her career she
worked as an investment banker at Prudential Securities, and prior
to that was in the audit department of KPMG Peat Marwick. She holds
a B.S. in biology from Stanford University and an M.B.A. from the
Anderson School at the University of California, Los Angeles. Ms.
Dier serves on the Board of Directors of Adamas Pharmaceuticals,
ORIC Pharmaceuticals, and Prelude Therapeutics.
“Ultragenyx is a company truly dedicated to developing medicines
for patients with serious rare diseases and I am thrilled to join a
team so impassioned by its mission,” said Ms. Dier. “As a global
commercial company with an exciting and deep pipeline targeting a
number of diseases across multiple modalities, I look forward to
being part of this leadership team and helping further establish
Ultragenyx as a leading, global, and diversified rare disease
company."
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing
to patients novel products for the treatment of serious rare and
ultra-rare genetic diseases. The company has built a diverse
portfolio of approved therapies and product candidates aimed at
addressing diseases with high unmet medical need and clear biology
for treatment, for which there are typically no approved therapies
treating the underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s
website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.Investors
& MediaJoshua Higa(415) 475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2024 to May 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From May 2023 to May 2024